Nick Cleworth becomes cancer-free after immunotherapy drug in ARTEMIS bowel cancer trial
Updated
Updated · The Mirror · Apr 24
Nick Cleworth becomes cancer-free after immunotherapy drug in ARTEMIS bowel cancer trial
1 articles · Updated · The Mirror · Apr 24
Cleworth, 48, from Salford, saw his tumour eradicated without surgery after receiving palupiprant plus standard treatment at The Christie NHS Foundation Trust, as part of a 140-patient trial across 22 NHS sites.
The ARTEMIS phase II trial tests whether adding palupiprant to chemotherapy and radiotherapy improves rectal cancer outcomes, potentially eliminating the need for permanent colostomy bags in some patients.
Bowel cancer rates are rising among under-50s in England, with experts linking this to lifestyle factors. Earlier studies showed palupiprant eradicated cancer in 36% of participants, and NHS screening uptake has surged recently.
How can patients access this groundbreaking trial before considering life-altering surgery?
What are the hidden long-term risks of this new 'miracle' cancer drug?
Could changing our gut microbiome be more powerful than drugs in preventing bowel cancer?
With bowel cancer soaring in the young, what are the earliest warning signs everyone is missing?
Can health systems afford this revolutionary treatment if it becomes the new standard of care?
Is this new drug a cure, or a patch for a crisis caused by our modern diet?